AKTX (Akari Therapeutics) EBIT : $-27.26 Mil (TTM As of Sep. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Akari Therapeutics EBIT?

Akari Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was $-2.83 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was $-27.26 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Akari Therapeutics's annualized ROC % for the quarter that ended in Sep. 2024 was -271.85%. Akari Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Akari Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -122.37%.

Akari Therapeutics EBIT Historical Data

The historical data trend for Akari Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akari Therapeutics EBIT Chart

Akari Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-16.96

-17.98

-17.21

-23.09

-16.81

Akari Therapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT	Get a 7-Day Free Trial															-2.87	-10.94	-5.99	-7.51	-2.83

Competitive Comparison of Akari Therapeutics's EBIT

For the Biotechnology subindustry, Akari Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akari Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akari Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Akari Therapeutics's EV-to-EBIT falls into.

Akari Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-27.26 Mil.

Akari Therapeutics (NAS:AKTX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Akari Therapeutics's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

	ROC % (Q: Sep. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2024 )	+	Invested Capital (Q: Sep. 2024 ))	/ count )
=	-7.408 * ( 1 - 0% )	/	( (2.785	+	2.665)	/ 2 )
=	-7.408	/	2.725
=	-271.85 %

where

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	5.076	-	5.994	-	( 4.177	-	max(0, 8.779	-	5.076	+	4.177	))
=	2.785

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	2.734	-	6.763	-	( 2.246	-	max(0, 9.428	-	2.734	+	2.246	))
=	2.665

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Akari Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2024		Q: Sep. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-11.304	/	( ( (0 + max(-6.88, 0))	+	(0 + max(-7.94, 0)) )	/	2 )
=	-11.304	/	( ( 0	+	0 )	/	2 )
=	-11.304	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.899)	-	(5.994	+	0	+	1.785)
=	-6.88

	Working Capital		(Q: Sep. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.488)	-	(6.763	+	0	+	1.665)
=	-7.94

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Akari Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2024 )
	=	-27.258	/	22.275
	=	-122.37 %

Akari Therapeutics EBIT Related Terms

Thank you for viewing the detailed overview of Akari Therapeutics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Akari Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akari Therapeutics PLC (NAS:AKTX) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

CLA:Germany

Address

22 Boston Wharf Road, Boston, MA, USA, 02210

Website

https://www.akaritx.com

Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).

Executives

Donald Allen Williams	director	C/O PRYOR CASHMAN LLP, 7 TIMES SQUARE, NEW YORK NY 10036
David Byrne	director	C/O AKARI THERAPEUTICS, PLC, 24 WEST 40TH STREET, 8TH FLOOR, NEW YORK NY 10018
Robert M Shaw	officer: General Counsel and Secretary	C/O BIOTECHNOLOGY GENERAL CORP, ONE TOWER CENTER BLVD 14TH FLR, EAST BRUNSWICK NJ 08816
Clive Richardson	director, officer: COO	C/O LANDMARK FIDUCIAIRE (SUISSE) SA, 6 PLACE DES EAUX-VIVES, PO BOX 3461, GENEVA V8 1211
Rpc Pharma Ltd	10 percent owner	C/O LANDMARK FIDUCIAIRE (SUISSE) SA, 6 PLACE DES EAUX-VIVES, PO BOX 3461, GENEVA V8 1211
Ray Prudo	director, 10 percent owner	C/O LANDMARK FIDUCIAIRE (SUISSE) SA, 6 PLACE DES EAUX-VIVES, PO BOX 3461, GENEVA V8 1211
Stuart Ungar	director, 10 percent owner	C/O LANDMARK FIDUCIAIRE (SUISSE) SA, 6 PLACE DES EAUX-VIVES, PO BOX 3461, GENEVA V8 1211
James Hill	director, 10 percent owner	C/O LANDMARK FIDUCIAIRE (SUISSE) SA, 6 PLACE DES EAUX-VIVES, PO BOX 3461, GENEVA V8 1211
Mark S Cohen	director	C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
Allan Shaw	director	C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
Dov Elefant	officer: Chief Financial Officer	EPICEPT CORPORATION, 270 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632
Gur Roshwalb	director, officer: Chief Executive Officer	C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
David Sidransky	director	JOHNS HOPKINS UNIVERSITY, 720 RUTLAND AVENUE, BALTIMORE MD 21205
Amos Eiran	director	C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
Lau Johnson Yiu Nam	director